Novartis mRNA Bet Puts Pipeline Governance on Trial
Novartis is paying $575 million upfront for Abogen’s mRNA platform while keeping most of a $7.8 billion headline contingent. The real test is disciplined…
Read the storyTag: mRNA
Alphabet Technical Analysis: $340 Pivot Faces a Breakout Test
The Vistra Nuclear Loan Turns Reactor Uprates Into a Finance Test
The AI Safety Pact Turns Governance Into a Valuation Test
B2L Market Focus: Record ETF Inflows Are Rewiring Market Demand
zkAPI Breaks the Billing Link, Not the AI Privacy Problem
Amazon Technical Analysis: $253.40 Tests the 50 Day EMA
Generali’s 9.9% Cajamar Stake Turns Bancassurance Into a Control Test
The M&A Boom Is Hitting a Cost of Capital Wall
Novartis is paying $575 million upfront for Abogen’s mRNA platform while keeping most of a $7.8 billion headline contingent. The real test is disciplined…
Read the story